Retroperitoneal lymph node dissection for testicular seminomas: population-based practice and survival outcomes

Hiten D. Patel*, Gregory A. Joice, Zeyad R. Schwen, Alice Semerjian, Ridwan Alam, Arnav Srivastava, Mohamad E. Allaf, Phillip M. Pierorazio

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Purpose: While retroperitoneal lymph node dissection (RPLND) is traditionally reserved for nonseminomatous germ cell tumors, recent efforts to reduce long-term toxicities of radiation and chemotherapy have turned attention to its application for testicular seminomas. Currently, RPLND is reserved for the post-chemotherapy for stage II testicular seminomas; we aimed to describe current utilization of RPNLD for testicular seminomas by stage and implications for survival. Methods: A national sample of men diagnosed with stage IA/IB/IS/IIA/IIB/IIC testicular seminoma (1988–2013) was evaluated from SEER Program registries. Stage-specific utilization of RPLND was determined. Cox proportional hazards models, adjusted for age, race, and radiotherapy, evaluated overall (OS) and cancer-specific survival (CSS) for the RPLND cohort. Adjusted models assessed predictors of RPLND. Results: A total of 17,681 men (mean age 38.1 years) with testicular seminoma were included with low utilization of RPLND for stage I disease (1.3% overall) and higher rates for stage II disease (10.6% overall). There were no appreciable trends over time. Patients receiving RPLND did not appear to have worse OS or CSS on adjusted stage-by-stage analysis. Higher stage disease (IIA-IIC) was associated with greater need for RPLND while radiotherapy was associated with decreased use [OR 0.40 (0.32–0.51), p < 0.001]. Conclusions: Utilization of RPLND for testicular seminomas in the post-chemotherapy setting has remained stable over a 25-year period. Patients undergoing RPLND are a higher risk cohort but stage-by-stage survival outcomes appeared comparable to men not undergoing RPLND. Upcoming trials implementing RPLND as a first-line modality for testicular seminoma or isolated retroperitoneal relapse will help better quantify relative recurrence and survival.

Original languageEnglish (US)
Pages (from-to)73-78
Number of pages6
JournalWorld journal of urology
Issue number1
StatePublished - Jan 1 2018


  • Retroperitoneal lymph node dissection
  • Testicular cancer
  • Testicular seminoma

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Retroperitoneal lymph node dissection for testicular seminomas: population-based practice and survival outcomes'. Together they form a unique fingerprint.

Cite this